hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 14:39:49 - browse：8

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA's Woodcock to retire early next year

WSS

PBM reforms clear House panel

Surge of respiratory disease in China has likely explanation

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

A daunting task: navigating dual Medicare, Medicaid eligibility

Woman returns to dialysis after doctors remove transplanted pig kidney

Readout LOUD podcast: A CRISPR milestone, biotech mixology

focus

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Woman returns to dialysis after doctors remove transplanted pig kidney

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Bright Health sells Medicare Advantage business to Molina

David Sabatini, ex

focus

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

FDA's Pazdur wants cancer trials to range beyond China alone

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO: Palliative care found as helpful given virtually as in person

entertainment

knowledge

entertainment

focus